Intranasal Insulin for Posttraumatic Stress Disorder

Description

To evaluate if intranasal insulin is effective in reducing PTSD symptoms.

Conditions

PTSD

Study Overview

Study Details

Study overview

To evaluate if intranasal insulin is effective in reducing PTSD symptoms.

Intranasal Insulin for Treating Posttraumatic Stress Disorder

Intranasal Insulin for Posttraumatic Stress Disorder

Condition
PTSD
Intervention / Treatment

-

Contacts and Locations

West Haven

VA Connecticut Healthcare System, West Haven, Connecticut, United States, 06516

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Male or female, 21-65 years old
  • * Current PTSD
  • * Able to provide written informed consent
  • * Unstable medical condition, clinically determined by a physician
  • * Diabetes requiring insulin or oral hypoglycemic agents
  • * Moderate-severe traumatic brain injury
  • * Current psychotic disorder, bipolar disorder, cognitive disorder in the past 12 months
  • * Current substance use disorders (except alcohol, tobacco, or cannabis) in the past 3 months
  • * Changes in doses of psychotropic medications in the past 4 weeks
  • * Initiation of individual therapy or counseling in the past 4 weeks
  • * Imminent suicidal or homicidal risk
  • * Contraindication to Insulin
  • * History of claustrophobia
  • * Presence of cardiac pacemaker or other electronic device or ferromagnetic metal foreign bodies in vulnerable positions as assessed by a standard pre-MRI safety screening questionnaire

Ages Eligible for Study

21 Years to 65 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

VA Connecticut Healthcare System,

Gihyun Yoon, MD, PRINCIPAL_INVESTIGATOR, VA Connecticut Healthcare System

Study Record Dates

2025-05-31